Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that cabozantinib (Cabometyx ® ), irinotecan liposome injection (Onivyde ® ), lanreotide (Somatuline ® ) and the combination of lanreotide and telotristat (Xermelo ® ) are the subject of 12 presen...
Ipsen Canada Appoints Ed Dybka as General Manager Canada NewsWire MISSISSAUGA, ON, Oct. 11, 2018 MISSISSAUGA, ON , Oct. 11, 2018 /CNW/ - Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dy...
– Studies Demonstrate Ipsen’s Commitment to Ongoing Innovation and Improving Patient Care in the Neuroendocrine Tumor (NETs) Space – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that seven studies have been selected fo...
– Ipsen now part of the largest association of biotechnology companies, academic institutions and biotech centers – Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced it has joined the Biotechnology Innovation Organization (BIO), the l...
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx ® (cabozantinib) as a monotherapy for the trea...
Ipsen S.A. ADR (IPSEY) Q2 2018 Earnings Conference Call July 26, 2018, 07:30 AM ET Executives David Meek - CEO and Director Aymeric Le Chatelier - CFO Analysts James Quigley - JP Morgan Matthew Weston - Crédit Suisse Peter Welford - Jefferies Gary Steventon - Exane...
The following slide deck was published by Ipsen S.A. ADR in conjunction with their 2018 Q2 earnings Read more ...
Ipsen S.A. ADR ( OTCPK:IPSEY ): 1H EPS of €2.86 More news on: Ipsen S.A. ADR, Earnings news and commentary, Healthcare stocks news, Read more ...
Sales growth of 26.7% 1 for Specialty Care and 2.0% 1,2 for Consumer Healthcare Core Operating Income growth of 34.1% Upgraded full year 2018 guidance of Group sales growth greater than 19.0% 1 (versus prior guidance greater than 16.0%) and Core operating margin of around 29.0% ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...